<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>SEC</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>US med-tech company begins restoration after cyber strike</title>
      <description>
        <![CDATA[Stryker Corp. is scrambling to recover from a cyberattack that’s disrupting its global network and being claimed by pro-Iranian hackers. “At this time, there is no indication of malware or ransomware, and we believe the situation is contained to our internal Microsoft environment only,” the Kalamazoo, Mich.-based med-tech company said March 12.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729479</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729479-us-med-tech-company-begins-restoration-after-cyber-strike</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cyber-attack-tech-alert.webp?t=1773347023" type="image/jpeg" medium="image" fileSize="689386">
        <media:title type="plain">Red error exclamation point over binary code background</media:title>
      </media:content>
    </item>
    <item>
      <title>Pharma company, execs charged with securities fraud </title>
      <description>
        <![CDATA[The SEC filed civil charges against CBA Pharma Inc. and two top executives in U.S. district court, alleging they conducted a fraudulent securities offering that raised about $4.1 million from nearly 160 investors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728808</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728808-pharma-company-execs-charged-with-securities-fraud</link>
    </item>
    <item>
      <title>Hair loss drugmaker Veradermics floats upsized $256M US IPO</title>
      <description>
        <![CDATA[Veradermics Inc. raised $256.3 million from an IPO on the New York Stock Exchange Feb. 4. The proceeds will fund three ongoing phase II/III clinical trials of VDPHL-01, its novel oral formulation of Rogaine (minoxidil) to treat pattern hair loss in men and women.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728557</guid>
      <pubDate>Wed, 04 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728557-hair-loss-drugmaker-veradermics-floats-upsized-256m-us-ipo</link>
    </item>
    <item>
      <title>Eikon Therapeutics seeks up to $317M raise in Nasdaq IPO</title>
      <description>
        <![CDATA[Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, Calif.-based biopharma company would raise about $317.7 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728477</guid>
      <pubDate>Thu, 29 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728477-eikon-therapeutics-seeks-up-to-317m-raise-in-nasdaq-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Going-public-ticker.webp?t=1601061733" type="image/png" medium="image" fileSize="617241">
        <media:title type="plain">Going public ticker</media:title>
      </media:content>
    </item>
    <item>
      <title>Former Cytodyn CEO faces prison time, millions in restitution</title>
      <description>
        <![CDATA[Nader Pourhassan, the former president and CEO of Cytodyn Inc., was sentenced Jan. 23 to 30 months in prison for his role in a securities fraud scheme to deceive investors about the Vancouver, Wash.-based company’s development of leronlimab as a treatment for HIV and COVID-19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728505</guid>
      <pubDate>Tue, 27 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728505-former-cytodyn-ceo-faces-prison-time-millions-in-restitution</link>
    </item>
    <item>
      <title>Put options put biopharma researcher in SEC hot water </title>
      <description>
        <![CDATA[Another day, another insider trading settlement involving a biopharma company employee. This time the U.S. SEC settlement is with Mohit Verma, who was a researcher and associate director of immunology at the San Diego-based Infinitybio Inc. at the time of the alleged violative trading activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728149</guid>
      <pubDate>Thu, 22 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728149-put-options-put-biopharma-researcher-in-sec-hot-water</link>
    </item>
    <item>
      <title>Misleading statements result in civil penalties for Spero execs</title>
      <description>
        <![CDATA[Two former Spero Therapeutics Inc. executives are on the hook for a total of $187,500 in civil penalties in a settlement resolving U.S. SEC allegations of issuing misleading statements centered on the FDA’s evaluation of Spero’s lead drug candidate that resulted in a 64% stock drop in May 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728021</guid>
      <pubDate>Tue, 20 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728021-misleading-statements-result-in-civil-penalties-for-spero-execs</link>
    </item>
    <item>
      <title>Biopharma consultant charged with insider trading </title>
      <description>
        <![CDATA[A biostatistician who was consulting for C4 Therapeutics Inc. is facing civil and criminal charges of U.S. securities fraud related to insider trading that allegedly produced nearly $500,000 in profit.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727996</guid>
      <pubDate>Thu, 15 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727996-biopharma-consultant-charged-with-insider-trading</link>
    </item>
    <item>
      <title>Advanced Biomed sells Hong Kong subsidiary for $23k </title>
      <description>
        <![CDATA[Advanced Biomed Inc. reported Dec. 30 the sale of its wholly owned Hong Kong subsidiary, Advanced Biomed (HK) Ltd., and related intellectual property to buyer Wei Ha Hui for $23,000.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727303</guid>
      <pubDate>Wed, 31 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727303-advanced-biomed-sells-hong-kong-subsidiary-for-23k</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Advanced-Biomeds-APerfusc-3D-cell-culture-system-(hero)-12-31.webp?t=1767210422" type="image/jpeg" medium="image" fileSize="256616">
        <media:title type="plain">Advanced Biomed’s A+Perfusc 3D cell culture system</media:title>
        <media:description type="plain">Advanced Biomed’s A+Perfusc 3D cell culture system
</media:description>
      </media:content>
    </item>
    <item>
      <title>Feds break up alleged stock manipulation ring targeting biopharma</title>
      <description>
        <![CDATA[Six individuals, including an investment banker, face multiple U.S. charges stemming from an alleged $41 million insider-trading scheme, plus stock manipulation schemes involving biopharma companies. The charges are related to three overlapping securities fraud schemes that occurred between June 2020 and February 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727356</guid>
      <pubDate>Tue, 23 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727356-feds-break-up-alleged-stock-manipulation-ring-targeting-biopharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Pills-syringes-financial-charts.webp?t=1712350065" type="image/jpeg" medium="image" fileSize="287058">
        <media:title type="plain">Pills, syringes, financial charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Pomdoctor closes $20M IPO to grow mobile health platform in China</title>
      <description>
        <![CDATA[Pomdoctor Ltd. raised $20 million through a Nasdaq IPO on Oct. 8, with the funds geared to expand its mobile health platform for chronic diseases in China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724830</guid>
      <pubDate>Fri, 10 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724830-pomdoctor-closes-20m-ipo-to-grow-mobile-health-platform-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Pomdoctor-10oct25.webp?t=1760130283" type="image/jpeg" medium="image" fileSize="248601">
        <media:title type="plain">Pomdoctor</media:title>
        <media:description type="plain">Pomdoctor</media:description>
      </media:content>
    </item>
    <item>
      <title>Biopharmas launch new crypto financing strategies</title>
      <description>
        <![CDATA[With half-year industry financings down 59% from last year, and a U.S. administration supportive of cryptocurrencies, biopharma companies are building treasuries of digital assets to secure future R&D efforts and operational runways. Companies such as Artelo Biosciences Inc., MEI Pharma Inc., Windtree Therapeutics Inc. and 180 Life Sciences Corp. and have entered crypto deals in recent weeks, with the latter noting the potential to “unlock value outside traditional biotech milestones.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/722935</guid>
      <pubDate>Thu, 07 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722935-biopharmas-launch-new-crypto-financing-strategies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Cryptocurrency-illustration.webp?t=1754599433" type="image/jpeg" medium="image" fileSize="712487">
        <media:title type="plain">Bitcoin surrounded by coins and financial charts, symbolizing cryptocurrency and digital investment</media:title>
      </media:content>
    </item>
    <item>
      <title>Jyong’s $20M US IPO to help refile NDA of urological botanic drug</title>
      <description>
        <![CDATA[Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721538</guid>
      <pubDate>Tue, 24 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721538-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug</link>
    </item>
    <item>
      <title>Jyong’s $20M US IPO to help refile NDA of urological botanic drug</title>
      <description>
        <![CDATA[Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721456</guid>
      <pubDate>Wed, 18 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721456-jyongs-20m-us-ipo-to-help-refile-nda-of-urological-botanic-drug</link>
    </item>
    <item>
      <title>Apimeds Pharmaceuticals raises $13.5M from NYSE American debut</title>
      <description>
        <![CDATA[Apimeds Pharmaceuticals US Inc. (APUS), a subsidiary of Kospi-listed Inscobee Inc., said May 12 that it raised $13.5 million from its stock sale on the NYSE American exchange May 9 through an offering of 3.375 million shares at $4 per share. Hopewell, N.J.-based APUS is the second pharmaceutical company with Asian ties to float shares on the U.S. market this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720492</guid>
      <pubDate>Tue, 20 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720492-apimeds-pharmaceuticals-raises-135m-from-nyse-american-debut</link>
    </item>
    <item>
      <title>Apimeds Pharmaceuticals raises $13.5M from NYSE American debut</title>
      <description>
        <![CDATA[Apimeds Pharmaceuticals US Inc. (APUS), a subsidiary of Kospi-listed Inscobee Inc., said May 12 that it raised $13.5 million from its stock sale on the NYSE American exchange May 9 through an offering of 3.375 million shares at $4 per share. Hopewell, N.J.-based APUS is the second pharmaceutical company with Asian ties to float shares on the U.S. market this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720119</guid>
      <pubDate>Wed, 14 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720119-apimeds-pharmaceuticals-raises-135m-from-nyse-american-debut</link>
    </item>
    <item>
      <title>SEC scores $17M win over investor fraud allegations</title>
      <description>
        <![CDATA[The U.S. Securities and Exchange Commission said it obtained a judgment for a total of $17 million in penalties and disgorgement from a group of individuals and entities charged with investor fraud. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/719528</guid>
      <pubDate>Wed, 30 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719528-sec-scores-17m-win-over-investor-fraud-allegations</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/regulatory-whistleblower-gavel-law.webp?t=1628889529" type="image/png" medium="image" fileSize="1356560">
        <media:title type="plain">Gavel with whistle</media:title>
      </media:content>
    </item>
    <item>
      <title>US capital crunch pushes China biotechs to roundabout financings</title>
      <description>
        <![CDATA[Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719777</guid>
      <pubDate>Tue, 29 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719777-us-capital-crunch-pushes-china-biotechs-to-roundabout-financings</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.webp?t=1651786531" type="image/png" medium="image" fileSize="321453">
        <media:title type="plain">China in red on globe</media:title>
      </media:content>
    </item>
    <item>
      <title>US capital crunch pushes China biotechs to roundabout financings</title>
      <description>
        <![CDATA[Tightening of U.S. regulation and capital is leading Chinese biotechs to alternative and new models of financing, ranging from cross-border licensing deals, M&As, the so-called newco model and overseas listings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719490</guid>
      <pubDate>Thu, 24 Apr 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719490-us-capital-crunch-pushes-china-biotechs-to-roundabout-financings</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.webp?t=1651786531" type="image/png" medium="image" fileSize="321453">
        <media:title type="plain">China in red on globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Former Acadia exec pleads guilty to insider trading</title>
      <description>
        <![CDATA[George Demos, former vice president of drug safety and pharmacovigilance at Acadia Pharmaceuticals Inc., is the latest biopharma executive to plead guilty to insider trading charges.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718080</guid>
      <pubDate>Mon, 10 Mar 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718080-former-acadia-exec-pleads-guilty-to-insider-trading</link>
    </item>
    <item>
      <title>Basel Medical prices $8.8M IPO</title>
      <description>
        <![CDATA[Basel Medical Group Ltd. is the first Singapore-based med-tech to price an IPO on the Nasdaq this year, aggregating gross proceeds of $8.82 million on its debut. The funds will be used to power future M&As and business expansion plans in Singapore and Southeast Asia, the company said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718015</guid>
      <pubDate>Tue, 04 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/718015-basel-medical-prices-88m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/asia-singapore.webp?t=1588615605" type="image/png" medium="image" fileSize="388073">
        <media:title type="plain">Singapore</media:title>
      </media:content>
    </item>
    <item>
      <title>Basel Medical prices $8.8M IPO</title>
      <description>
        <![CDATA[Basel Medical Group Ltd. is the first Singapore-based med-tech to price an IPO on the Nasdaq this year, aggregating gross proceeds of $8.82 million on its debut. The funds will be used to power future M&As and business expansion plans in Singapore and Southeast Asia, the company said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717621</guid>
      <pubDate>Thu, 27 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717621-basel-medical-prices-88m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/asia-singapore.webp?t=1588615605" type="image/png" medium="image" fileSize="388073">
        <media:title type="plain">Singapore</media:title>
      </media:content>
    </item>
    <item>
      <title>Insider trades on sales data result in US SEC settlement</title>
      <description>
        <![CDATA[A former regional sales director at Lantheus Holdings Inc. is the latest biopharma official to settle insider trading charges with the U.S. SEC. As part of the settlement, John Heropoulos agreed to disgorge nearly $61,000, an equal amount in civil penalties and more than $10,000 in prejudgment interest, according to the SEC.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716686</guid>
      <pubDate>Tue, 28 Jan 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716686-insider-trades-on-sales-data-result-in-us-sec-settlement</link>
    </item>
    <item>
      <title>Humanigen execs face US insider trading charges</title>
      <description>
        <![CDATA[Rounding out a year of insider trading charges involving biopharma companies, the U.S. SEC reported Dec. 30 that it had filed a complaint against two top Humanigen Inc. executives, Cameron Durrant, CEO, and Dale Chappell, chief science officer,
 for trades based on insider knowledge of FDA actions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715905</guid>
      <pubDate>Tue, 31 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715905-humanigen-execs-face-us-insider-trading-charges</link>
    </item>
    <item>
      <title>Two more biopharma insider trading cases resolved </title>
      <description>
        <![CDATA[A principal investigator and a former biopharma executive are the latest to reach settlements with the SEC to resolve charges of insider trading involving drug companies. Sai-Hong Ignatius Ou, of the University of California Irvine, agreed to a judgment ordering him to disgorge more than $1.5 million and to pay a civil penalty of the same amount. In a separate, unrelated settlement, Curt Dewitz, a former executive of an undisclosed biopharma company, agreed to disgorge about $70,383 in unlawful profits.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715682</guid>
      <pubDate>Thu, 19 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715682-two-more-biopharma-insider-trading-cases-resolved</link>
    </item>
    <item>
      <title>Jury convicts biotech execs in fraud scheme</title>
      <description>
        <![CDATA[Nearly three years after being terminated as president and CEO of Cytodyn Inc., Nader Pourhassan was convicted June 9 by a U.S. federal jury for his role in a securities fraud scheme to deceive investors about the Vancouver, Wash.-based company’s development of leronlimab. The jury also convicted Kazem Kazempour, the CEO of Amarex Clinical Research LLC, a contract research organization hired by Cytodyn, for his part in the scheme.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715260</guid>
      <pubDate>Wed, 11 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715260-jury-convicts-biotech-execs-in-fraud-scheme</link>
    </item>
    <item>
      <title>Investment advisers face fraud charges in Biovie trading</title>
      <description>
        <![CDATA[The U.S. SEC filed charges against David Banister and The Market Analysts Group LLC, which Banister controls, alleging that they conducted a fraudulent scheme to promote long-term investment in Biovie Inc. without disclosing that Banister was actively selling his own shares in the biopharma company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715337</guid>
      <pubDate>Tue, 10 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715337-investment-advisers-face-fraud-charges-in-biovie-trading</link>
    </item>
    <item>
      <title>Kiromic’s nondisclosure of clinical hold leads to SEC settlements</title>
      <description>
        <![CDATA[Kiromic Biopharma Inc. and two former senior officials have settled with the U.S. SEC to resolve charges involving nondisclosure of U.S. FDA clinical holds on two cancer candidates before and after a July 2021 follow-on public offering that raised $40 million the company desperately needed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714888</guid>
      <pubDate>Tue, 03 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714888-kiromics-nondisclosure-of-clinical-hold-leads-to-sec-settlements</link>
    </item>
    <item>
      <title>Change is the constant in wake of US elections</title>
      <description>
        <![CDATA[The drug and device industries have a lot hinging on the results of the Nov. 5 U.S. presidential and congressional elections. Tax policies. The reach of the FTC. Legislation aimed at drug prices, competition, pharmacy benefit managers and lab-developed tests. Cabinet and agency appointments that could reshape Medicare drug negotiations, the 340B program, FDA Orange Book device patent listings, regulatory flexibility and Bayh-Dole march-ins. And that’s just the top of the list.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714121</guid>
      <pubDate>Fri, 01 Nov 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/714121-change-is-the-constant-in-wake-of-us-elections</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/US-election-illustration.webp?t=1709072440" type="image/jpeg" medium="image" fileSize="179830">
        <media:title type="plain">Hand holding ballot over box, US flag backdrop</media:title>
      </media:content>
    </item>
    <item>
      <title>Former Bellus Health exec consents to insider trading judgment</title>
      <description>
        <![CDATA[The U.S. SEC filed insider trading charges against Ruimin Xie, the former director of analytical development at Bellus Health Inc., for allegedly receiving ill-gotten gains of $59,408.42 by acting on word of a potential acquisition by GSK plc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713637</guid>
      <pubDate>Fri, 18 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713637-former-bellus-health-exec-consents-to-insider-trading-judgment</link>
    </item>
  </channel>
</rss>
